Parenteral delivery of peptides and proteins

Biodrug Delivery Systems: Fundamentals, Applications and Clinical Development

Volumn , Issue , 2016, Pages 50-68

  Rawat, Archana ^a   Burgess, Diane J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINS;

EID: 84947267938     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (83)

1. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release 2003; 90(3):261-280.
2. Brown LR. Commercial challenges of protein drug delivery. Expert Opin Drug Deliv 2005; 2(1):29-42.
3. Costantino HR, Liauw S, Mitragotri S, et al. The pharmaceutical development of insulin: historical perspective and future directions. In: Shahrokh Z, Sluzky V, Cleland J, et al., eds. Therapeutic Protein and Peptide Formulation and Delivery. ACS Symposium Series. Washington, D.C.: American Chemical Society, 1997:29-66.
4. Cleland JL, Daugherty A, Mrsny R. Emerging protein delivery methods. Curr Opin Biotechnol 2001; 12(2):212-219.
5. van de Weert M, Jorgensen L, Moeller EH, et al. Factors of importance for a successful delivery system for proteins. Expert Opin Drug Deliv 2005; 2 (6):1029-1037.
6. Shantha Kumar TR, Soppimath K, Nachaegari SK. Novel delivery technologies for proteins and peptide therapeutics. Curr Pharm Biotechnol 2006; 7:261-276.
7. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res 1989; 6(11):903-918.
8. Krishnamurthy R, Manning MC. The stability factor: importance in formulation development. Curr Pharm Biotechnol 2002; 3(4):362-372.
9. Murphy RM, Tsai AM. Protein folding, misfolding, stability and aggregation. In: Murphy RM, Tsai AM, eds. Misbehaving Proteins. New York: Springer, 2006:3-13.
10. Schoneich C, Hageman MJ, Borchardt RT. Stability of peptides and proteins. In: Park K, ed. Controlled Drug Delivery. Washington D.C.: American Chemical Society, 1997:205-228.
11. Banerjee PS, Hosny EA, Robinson JR. Parenteral delivery of peptide and protein drugs. In: Lee VHL, ed. Peptide and Protein Drug Delivery. New York: Marcel Dekker, 1991:487-543.
12. Casadevall N, Eckardt K, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005; 16:67-69.
13. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005; 20(6):vi3-vi9.
14. Kropshofer H, Singer T. Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics. J Immunotoxicol 2006; 3(3):131-136.
15. Orive G, Hernandez RM, Gascon AR, et al. Drug delivery in biotechnology: present and future. Curr Opin Biotechnol 2003; 14:659-664.
16. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 2006; 11(19-20):905-910.
17. Jorgensen L, Moeller EH, van de Weert M, et al. Preparing and evaluating delivery systems for proteins. Eur J Pharm Sci 2006; 29(3-4):174-182.
18. Kompella UB. Protein drug delivery. In: Wu-Pong S, Rojanasakul Y, eds. Biopharmaceutical Drug Design and Development. New Jersey: Humana Press, 1999:239-273.
19. Malik AB, Siflinger-Birnboim A. Vascular endothelial barrier function and its regulation. In: Audus KL, Raub TJ, eds. Biological Barrier to Protein Delivery. New York: Plenum, 1993:231-267.
20. Wang M, Hemminki A, Siegal GP, et al. Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. Gynecol Oncol 2005; 96(2):341-348.
21. Akers MJ, Defelippis MR. Peptides and proteins as parenteral solutions. In: Frokjaer S, Hovgaard L, eds. Pharmaceutical Formulation Development of Peptides and Proteins. Philadelphia: Taylor & Francis, 2000:145-177.
22. McGoff P, Scher DS. Solution formulation of proteins/peptides. In: McNally EJ, ed. Protein Formulation and Delivery. New York: Marcel Dekker, 2000:139-158.
23. Banga AK. Stability of therapeutic peptides and proteins. In: Banga AK, ed. Therapeutic Peptides and Proteins. Taylor & Francis, 2006:67-89.
24. Nail SL. Formulation of proteins and peptides. In: Park K, ed. Controlled Drug Delivery. Washington D.C.: American Chemical Society, 1997:185-203.
25. Banga AK. Structure and analysis of therapeutic peptides and proteins. In: Banga AK, ed. Therapeutic Peptides and Proteins. Boca Raton, FL: Taylor & Francis, 2006:33-65.
26. Banga AK. Preformulation and formulation of therapeutic peptides and proteins. In: Banga AK, ed. Therapeutic Peptides and Proteins. Boca Raton, FL: Taylor & Francis, 2006:91-138.
27. Kendrick BS, Li T, Chang BS. Physical stabilization of proteins in aqueous solutions. In: Carpenter JF, manning MC, eds. Rational Design of Stable Protein Formulations. New York: Kluwer Academics/Plenum Publishers, 2002:61-83.
28. Wang W, Wang YJ, Wang DQ. Dual effects of tween 80 on protein stability. Int J Pharm 2008; 347(1-2):31-38.
29. Carpenter JF, Chang BS, Garzon-Rodriguez W, et al. Rational design of stable lyophilized protein formulations: theory and practice. In: Carpenter JF, Manning MC, eds. Rational Design of Stable Protein Formulations. New York: Kluwer Academic/ Plenum Publishers, 2002:109-133.
30. Banga AK. Lyophilization, pharmaceutical processing and handling of therapeutic peptides and proteins. In: Banga AK, ed. Therapeutic Peptides and Proteins. Boca Raton, FL: Taylor & Francis, 2006:139-176.
31. Arakawa T, Timasheff SN. Stabilization of protein structure by sugars. Biochemistry 1982; 21:6536-6544.
32. Chang L, Shephard D, Sun J, et al. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and immobilization in a glassy matrix. J Pharm Sci 2005; 94:1427-1444.
33. Banga AK. Parenteral controlled delivery and pharmacokinetics of therapeutic peptides and proteins. In: Banga AK, ed. Therapeutic Peptides and Proteins. Boca Raton, FL: Taylor & Francis, 2006:177-227.
34. Yang L, Shi CH, Chang YY, et al. Entrapment of recombinant staphylokinase by liposomes: formulations, preparation, characterization and behavior in vivo. J Drug Deliv Sci Technol 2008; 18(4):245-251.
35. Marin FJ. Case study: DOXIL, the development of pegylated liposomal doxrubucin. In: Burgess DJ, ed. Injectable Dispersed Systems. Boca Raton, FL: Taylor & Francis, 2005:427-480.
36. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Drug Deliv Syst 2001; 40(7):539-551.
37. Packhaeuser CB, Schnieders J, Oster CG, et al. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004; 58:445-455.
38. Wright JC, Leonard ST, Stevenson CL, et al. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J Control Release 2001; 75:1-10.
39. Ye Q, Asherman J, Stevenson M, et al. DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. J Control Release 2000; 64:155-166.
40. Cross SE, Roberts MS. Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? Curr Drug Deliv 2004; 1(1):81-92.
41. Harsch IA. Inhaled insulin: their potential in the treatment of diabetes mellitus. Treat Endocrinol 2005; 4(3):131-138.
42. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003; 87:187-198.
43. Robertson KE, Glazer NB, Campbell RK. The latest developments in insulin injection devices. Diabetes Educ 2000; 26(1):135-138.
44. Fatouros A, Liden Y, Sjostrom B. Recombinant factor VIII SQ -stability of VIII:C in homogenates from porcine, monkey and human subcutaneous tissue. J Pharm Pharmacol 2000; 52(7):797-805.
45. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007; 59(6):478-490.
46. Dhalluin C, Ross A, Leuthold LA, et al. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug Chem 2005; 16(3):504-517.
47. Patil SD, Burgess DJ. Liposomes: design and manufacturing. In: Burgess DJ, ed. Injectable Dispersed Systems. Boca Raton, FL: Taylor & Francis, 2005:249-304.
48. Amin AF, Shah T, Patel J, et al. Non-invasive: insulin update. Drug Deliv Technol 2007; 7(3):3-7.
49. Drug Information Online (Drugs.Com). Available at: http://www.drugs.com. Accessed January 2009.
50. Electronic Medicines Compendium. Available at: http://emc.medicines.org.uk/. Accessed January 2009.
51. Monthly Prescribing Reference. Available at: http://www.empr.com/. Accessed January 2009.
52. Yuan L,Wang J, Shen WC. Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide. Pharm Res 2005; 22(2):220-227.
53. Renard E, P S-B, EVADIAC Group. Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab 2007; 33(2):158-166.
54. Clarke A, Dain M. Dose accuracy of a reusable insulin pen using a cartridge system with an integrated plunger mechanism. Expert Opin Drug Deliv 2006; 3(5):677-683.
55. Gopferich A. Polymer degradation and erosion: mechanisms and applications. Eur J Pharm Biopharm 1996; 42(1):1-11.
56. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995; 12(1):1-99.
57. Tice TR, Crossar DR. Biodegradable controlled-release parenteral systems. Pharm Res 1984; 11:26-35.
58. Lewis DH. Controlled Release of Bioactive Agents from Lactide/Glycolide Polymers. New York: Marcel Dekker, 1990.
59. Burgess DJ, Hickey AJ. Microspheres: design and manufacturing. In: Burgess DJ, ed. Injectable Dispersed Systems. Boca Raton, FL: Taylor & Francis, 2005.
60. Zolnik BS, Leary PE, Burgess DJ. Elevated temperature accelerated release testing of PLGA microspheres. J Control Release 2006; 112(3):293-300.
61. Wu XS. Synthesis and properties of biodegradable lactic/glycolic acid polymers. In: Wise DL, ed. Encyclopedic Handbook of Biomaterials and Bioengineering. New York: Marcel Dekker, 1995:1015-1054.
62. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21:2475-2490.
63. Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res 2004; 27(1):1-12.
64. Cleland JL, Johnson OL, Putney S, et al. Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv Drug Deliv Rev 1997; 28:71-84.
65. Shi Y, Li LC. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv 2005; 2(6):1039-1058.
66. Tracy MA. Case study: biodegradable microspheres for the sustained release of proteins. In: Burgess DJ, ed. Injectable Dispersed Systems. Boca Raton, FL: Taylor & Francis, 2005: 571-582.
67. Liang MT, Davies NM, Blanchfield JT, et al. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr Drug Deliv 2006; 3(4):379-388.
68. Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surfacemodified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 2006; 24(19):4201-5211.
69. Rosas JE, HernÄndez RM, Gascón AR, et al. Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66. Vaccine 2001; 19(31):4445.
70. Degim IT, Celebi N. Controlled delivery of peptides and proteins. Curr Pharm Des 2007; 13:99-117.
71. US Food and Drug Adminstration. Patient Information. Available at: http://www. fda.gov/medwatch/SAFETY/2003/03AUG_PI/Viadur.pdf. Accessed January 2009.
72. Kreye F, Siepmann F, Siepmann J. Lipid implants as drug delivery systems. Expert Opin Drug Deliv 2008; 5(3):291-307.
73. Oussoren C, Talsma H, Zuidema J, et al. Biopharmaceutical principles of injectable dispersed systems. In: Burgess DJ, ed. Injectable Dispersed Systems. Boca Raton, FL: Taylor & Francis, 2005:39-76.
74. Banga AK. Pulmonary and other mucosal delivery of therapeutic peptides and proteins. In: Banga AK, ed. Therapeutic Peptides and Proteins. Boca Raton, FL: Taylor & Francis, 2006:291-326.
75. Brain JD. Inhalation, deposition and fate of insulin and other therapeutic proteins. Diabetes Technol Ther 2007; 9:S4-S15.
76. Mack GS. Pfizer dumps Exubera. Nat Biotechnol 2007; 25:1331-1332.
77. Mudaliar S. Inhaled insulin using AERx1 insulin Diabetes Management System (AERx1 iDMS). Expert Opin Investig Drugs 2007; 16(10):1673-1681.
78. Su KSE. Nasal route of peptide and protein drug delivery. In: Lee VHL, ed. Peptide and Protein Drug Delivery. New York: Marcel Dekker, 1991:595-631.
79. Yu J, Kim S, Lee J, Chang J. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol 2008; 82(5):2350-2357.
80. Banga AK. Transdermal and topical delivery of therapeutic peptides and proteins. In: Banga AK, ed. Therapeutic Peptides and Proteins. Boca Raton, FL: Taylor & Francis, 2006:259-290.
81. Sudhakara Y, Kuotsua K, Bandyopadhyay AK. Buccal bioadhesive drug delivery-a promising option for orally less efficient drugs. J Control Release 2006; 114(1):15-40.
82. Senel S, Kremer M, Nagy K, et al. Delivery of bioactive peptides and proteins across oral (Buccal) mucosa. Curr Pharm Biotechnol 2001; 2:175-186.
83. Merkle HP, Anders R, Wermerskirchen A, et al. Buccal routes of peptide and protein drug delivery. In: Lee VHL, ed. Peptide and Protein Drug Delivery. New York: Marcel Dekker, 1991:545-578.